Revance Therapeutics Inc. (NASDAQ:RVNC) was down 3.3% on Thursday . The stock traded as low as $14.60 and last traded at $14.66, with a volume of 55,833 shares changing hands. The stock had previously closed at $15.16.

Several equities research analysts recently weighed in on RVNC shares. Zacks Investment Research cut Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 13th. Brean Capital restated a “buy” rating and set a $48.00 target price on shares of Revance Therapeutics in a report on Tuesday, May 24th. Guggenheim restated a “buy” rating and set a $55.00 target price on shares of Revance Therapeutics in a report on Tuesday, June 14th. Finally, SunTrust Banks Inc. dropped their target price on Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating for the company in a report on Tuesday, June 14th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Revance Therapeutics currently has an average rating of “Buy” and a consensus target price of $39.60.

The firm has a 50 day moving average of $14.03 and a 200-day moving average of $16.72. The firm’s market capitalization is $405.61 million.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.88) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.86) by $0.02. The business earned $0.80 million during the quarter, compared to analyst estimates of $0.06 million. The company’s revenue was up .0% compared to the same quarter last year. On average, equities analysts forecast that Revance Therapeutics Inc. will post ($3.53) earnings per share for the current year.

An institutional investor recently raised its position in Revance Therapeutics stock. Schwab Charles Investment Management Inc. boosted its stake in Revance Therapeutics Inc. (NASDAQ:RVNC) by 35.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 63,467 shares of the biopharmaceutical company’s stock after buying an additional 16,625 shares during the period. Schwab Charles Investment Management Inc. owned about 0.23% of Revance Therapeutics worth $2,169,000 as of its most recent SEC filing.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.